/
ABUS
$4.68+$0.10 (+2.18%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$904.7M
198M shares
52-week range
$3.04 – $5.10
80% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
CS
Borrow rate
0.40%
Easy to borrow
Price (6 mo)
Loading chart…
Change+$1.65
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $5.9M | $6.0M | $6.9M | $11.0M | $39.0M | $18.1M | $6.2M | $14.1M |
| Cost of revenue | $57.9M | $57.6M | $47.5M | $0 | $0 | $0 | $0 | $363.0K |
| Gross profit | −$52.0M | −$51.6M | −$40.6M | $11.0M | $39.0M | $18.1M | $6.2M | $13.7M |
| Gross margin | -881.4% | -858.3% | -586.7% | 100.0% | 100.0% | 100.0% | 100.0% | 97.4% |
| R&D | $57.9M | $57.6M | $49.3M | $65.5M | $84.4M | $73.7M | $54.0M | $25.2M |
| Operating income | −$89.8M | −$143.9M | −$57.8M | −$73.5M | −$65.5M | −$78.1M | −$76.3M | −$27.1M |
| EBITDA | −$59.0M | −$162.2M | −$57.8M | −$71.6M | −$61.9M | −$71.0M | −$68.4M | −$33.0M |
| Net income | −$57.1M | −$153.7M | −$63.7M | −$76.2M | −$69.5M | −$72.8M | −$69.9M | −$33.5M |
| Net margin | -967.8% | -2557.4% | -922.0% | -693.9% | -178.0% | -401.6% | -1133.0% | -237.9% |
| EPS (diluted) | -1.03 | -2.69 | -0.86 | -0.73 | -0.46 | -0.44 | -0.38 | -0.17 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $181M | $0.75 | $0.75–$0.75 | 1 |
| 2027 | $3M | $-0.09 | $-0.09–$-0.09 | 1 |
| 2028 | $56M | $-0.14 | $-0.14–$-0.14 | 1 |
| 2029 | $174M | $0.34 | $0.34–$0.34 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Arbutus Biopharma Corporation Common Stock
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes imdusiran (AB-729), a GalNAc-conjugated, subcutaneously delivered ribonucleic acid interference (RNAi) therapeutic, and AB-101, its proprietary oral PD-L1 inhibitor, for the treatment of chronic hepatitis B (cHBV). In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.
www.arbutusbio.com- Employees
- 19
- IPO / List date
- Jul 26, 2007
- HQ
- WARMINSTER, PA
Held by traders on TradeandTell
No one on the platform currently holds ABUS.
Super investors & insiders
Institutions holding (13F)
No tracked institution reports a position in ABUS as of their last filing.
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ABUS yet.
